2025
First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up of Chinese pts from CheckMate 649.
Shen L, Bai Y, Lin X, Li W, Wang J, Zhang X, Pan H, Bai C, Bai L, Cheng Y, Zhang J, Zhong H, Ba Y, Hu W, Xu R, Guo W, Qin S, Hu N, McCraith S, Liu T. First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up of Chinese pts from CheckMate 649. Journal Of Clinical Oncology 2025, 43: 392-392. DOI: 10.1200/jco.2025.43.4_suppl.392.Peer-Reviewed Original ResearchBlinded independent central reviewObjective response rateProgression-free survivalCombined positive scorePD-L1CheckMate 649Overall survivalFollow-upSurvival benefitPD-L1 combined positive scoreProgression-free survival benefitProgrammed death-ligand 1Long-term survival benefitStudy populationDual primary endpointsDeath-ligand 1Gastroesophageal junction cancerDuration of responseAdvanced gastric cancerIndependent central reviewOS ratesJunction cancerCentral reviewPrimary endpointFirst-lineNivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up results from CheckMate 649.
Janjigian Y, Moehler M, Ajani J, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Cleary J, Elimova E, Bruges R, Karamouzis M, Skoczylas T, Bragagnoli A, Liu T, Tehfe M, McCraith S, Hu N, Zhang J, Shitara K. Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 5-year (y) follow-up results from CheckMate 649. Journal Of Clinical Oncology 2025, 43: 398-398. DOI: 10.1200/jco.2025.43.4_suppl.398.Peer-Reviewed Original ResearchProgression-free survivalBlinded independent central reviewObjective response rateCombined positive scorePD-L1Overall survivalFollow-upCheckMate 649OS ratesPD-L1 combined positive scoreProgression-free survival benefitProgrammed death-ligand 1Anti-PD-1Death-ligand 1Duration of responseIndependent central reviewMinimum follow-upFollow-up resultsLong-term survivalOS benefitCentral reviewCombination therapyFirst-linePrimary endpointNivolumab
2024
419P Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Additional analyses from 4-year (y) follow-up (FU) of CheckMate 649
Wyrwicz L, Shitara K, Moehler M, Ajani J, Shen L, Garrido M, Araneda C, Yamaguchi K, Cleary J, Elimova E, Maya R, Karamouzis M, Skoczylas T, Bragagnoli A, Liu T, Tehfe M, Feeney K, Wang R, Zhang J, Janjigian Y. 419P Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Additional analyses from 4-year (y) follow-up (FU) of CheckMate 649. Annals Of Oncology 2024, 35: s169-s170. DOI: 10.1016/j.annonc.2024.05.333.Peer-Reviewed Original ResearchNivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649.
Elimova E, Shitara K, Moehler M, Ajani J, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Cleary J, Bruges Maya R, Karamouzis M, Skoczylas T, Bragagnoli A, Liu T, Tehfe M, Feeney K, Wang R, Nathani R, Janjigian Y. Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4-year follow-up of CheckMate 649. Journal Of Clinical Oncology 2024, 42: 4040-4040. DOI: 10.1200/jco.2024.42.16_suppl.4040.Peer-Reviewed Original ResearchProgression-free survivalBlinded independent central reviewCombined positive scoreObjective response ratePD-L1Overall survivalFollow-upCheckMate 649Clinically meaningful progression-free survivalPD-L1 combined positive scoreProgression-free survival benefitProgrammed death-ligand 1Dual primary endpointsHER2+ patientsDeath-ligand 1Analysis of OSIndependent central reviewLong-term efficacyFollow-up resultsEarly Follow-upClinically Meaningful ImprovementsMedian OSOS benefitPD-1Central reviewNivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649.
Shitara K, Moehler M, Ajani J, Shen L, Garrido M, Gallardo C, Wyrwicz L, Yamaguchi K, Cleary J, Elimova E, Bruges Maya R, Karamouzis M, Skoczylas T, Bragagnoli A, Liu T, Tehfe M, Feeney K, Wang R, Nathani R, Janjigian Y. Nivolumab (NIVO) + chemotherapy (chemo) vs chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): 4 year (yr) follow-up of CheckMate 649. Journal Of Clinical Oncology 2024, 42: 306-306. DOI: 10.1200/jco.2024.42.3_suppl.306.Peer-Reviewed Original ResearchProgression-free survivalBlinded independent central reviewCombined positive scoreObjective response ratePD-L1Overall survivalFollow-upCheckMate 649Clinically meaningful progression-free survivalPD-L1 combined positive scoreProgression-free survival benefitProgrammed death-ligand 1Dual primary endpointsHER2+ patientsDeath-ligand 1Analysis of OSIndependent central reviewLong-term efficacyFollow-up resultsEarly Follow-upClinically Meaningful ImprovementsMedian OSOS benefitPD-1Central reviewFirst-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis 4-year (yr) follow-up.
Shen L, Bai Y, Lin X, Li W, Wang J, Zhang X, Pan H, Bai C, Bai L, Cheng Y, Zhang J, Zhong H, Ba Y, Hu W, Xu R, Guo W, Qin S, Wang R, McCraith S, Liu T. First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): CheckMate 649 Chinese subgroup analysis 4-year (yr) follow-up. Journal Of Clinical Oncology 2024, 42: 318-318. DOI: 10.1200/jco.2024.42.3_suppl.318.Peer-Reviewed Original ResearchBlinded independent central reviewProgression-free survivalCombined positive scorePD-L1Overall survivalFollow-upCheckMate 649Safety profilePD-L1 combined positive scoreProgression-free survival benefitProgrammed death-ligand 1Clinically meaningful survival benefitStudy populationDual primary endpointsObjective response rateDeath-ligand 1Gastroesophageal junction cancerYrs of follow-upAdvanced gastric cancerIndependent central reviewOS ratesJunction cancerSurvival benefitCentral reviewFirst-line
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply